Effects of lopinavir-ritonavir combined therapy during the rat pregnancy morphological and biochemical aspects

被引:8
|
作者
Cunha, A. M.
Hagemann, C. C. F.
Simoes, R. S.
Oliveira-Filho, R. M.
Simoes, M. J.
Soares, J. M., Jr. [1 ]
Maciel, G. A. R.
Oliveira, F. H. M.
Amed, A. A.
Kulay, L., Jr.
机构
[1] Univ Fed Sao Paulo, Dept Obstet, Sch Med, Sao Paulo, Brazil
[2] Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, Sao Paulo, Brazil
[3] Univ Fed Sao Paulo, Dept Morphol, Sch Med, Sao Paulo, Brazil
[4] Univ Fed Sao Paulo, Dept Gynecol, Sch Med, Sao Paulo, Brazil
[5] Santa Casa Misericordia Sao Paulo, Sch Med, Sao Paulo, Brazil
关键词
lopinavir; ritonavir; toxicology; pregnancy; rat; HIV PROTEASE INHIBITORS; COMBINATION; TRANSMISSION; PLASMA; WOMEN;
D O I
10.1016/j.ejogrb.2006.08.004
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To evaluate the biochemical and morphological effects in rats subjected to three different dose associations of the protease inhibitors lopinavir and ritonavir administered throughout the entire period of pregnancy. Study design: The animals were treated throughout pregnancy with daily oral doses of lopinavir + ritonavir starting at the day one of pregnancy, and were divided into four groups: E1, 13.3 + 3.3 mg/kg; E2, 39.9 + 9.9 mg/kg; E3, 119.7 + 29.9 mg/kg and C, control (drug vehicle, propyleneglycol). The animals were then sacrificed and maternal blood and fetal and maternal organ samples were taken for morphological and biochemical analysis. Results: No major changes were identified in the group treated with the lowest dose as compared with the control. In the group E2, we found hepatocytes with signs of atrophy, eosinophilic cytoplasm, picnotic nuclei and vasodilatation. The proximal convoluted tubules of maternal kidneys showed eosinophilic areas and hyperchromatic nuclei, as well as signs of vasodilation. In the group treated with the highest dose (group E3), in the maternal kidneys and livers, the morphological changes were similar to those found in E2, although more prominent. Regarding the fetal organs, the single abnormality observed was some liver vasodilation in the group E3 (highest dose). The treatment with lopinavir + ritonavir caused discrete, yet significant, alterations of aspartate aminotransferase activity, blood urea nitrogen and creatinine plasma levels. Conclusions: Our results showed that the administration of a combination of lopinavir plus ritonavir to pregnant rats can cause morphological as well as functional changes in maternal and fetal liver and kidneys and, in higher than therapeutic doses, might be toxic to those animals. (C) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:60 / 63
页数:4
相关论文
共 50 条
  • [21] Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-Infected children
    Resino, S
    Galán, I
    Pérez, A
    Ramos, JT
    Bellón, JM
    Fontelos, PM
    De José, MI
    Gutiérrez, MDG
    Cabrero, E
    Muñoz-Fernández, MAM
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2005, 21 (05) : 398 - 406
  • [22] Randomized clinical trial: Combination antiretroviral therapy with tenofovir-emtricitabine and lopinavir-ritonavir in patients with primary biliary cholangitis
    Lytvyak, Ellina
    Hosamani, Ishwar
    Montano-Loza, Aldo J.
    Saxinger, Lynora
    Mason, Andrew L.
    CANADIAN LIVER JOURNAL, 2019, 2 (01):
  • [23] Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities
    Peixoto, Mario Ferreira
    Pilotto, Jose Henrique
    Stoszek, Sonia Karolina
    Kreitchmann, Regis
    Mussi-Pinhata, Marisa Marcia
    Melo, Victor Hugo
    Joao, Esau Custodio
    Ceriotto, Mariana
    de Souza, Ricardo da Silva
    Read, Jennifer
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2011, 15 (03): : 253 - 261
  • [24] Emergence of protease resistance during simplification therapy with lopinavir/ritonavir alone
    Sprinz, Eduardo
    Jeffman, Marcelo
    HIV CLINICAL TRIALS, 2007, 8 (02): : 105 - 106
  • [25] The maladaptive effects of HIV protease inhibitors (lopinavir/ritonavir) on the rat heart
    Reyskens, Kathleen M. S. E.
    Essop, M. Faadiel
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (03) : 3047 - 3049
  • [26] The Maladaptive Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir) on the Rat Heart
    Reyskens, Kathleen M. S. E.
    Fisher, Tarryn-Lee
    Schisler, Jonathan C.
    O'Connor, Wendi G.
    Rogers, Arlin B.
    Willis, Monte S.
    Planesse, Cynthia
    Rondeau, Philippe
    Bourdon, Emmanuel
    Essop, M. Faadiel
    PLOS ONE, 2013, 8 (09):
  • [27] Combination therapy of IFNβ1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients
    Baghaei, Parvaneh
    Dastan, Farzaneh
    Marjani, Majid
    Moniri, Afshin
    Abtahian, Zahra
    Ghadimi, Somayeh
    Valizadeh, Melika
    Heshmatnia, Jalal
    Mirenayat, Maryam Sadat
    Abedini, Atefeh
    Kiani, Arda
    Eslaminejad, Alireza
    Hashemian, Seyed MohammadReza
    Jamaati, Hamidreza
    Zali, Alireza
    Velayati, Ali Akbar
    Tabarsi, Payam
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 92
  • [28] Morphological and biochemical appraisal of the liver and renal effects of indinavir on rat pregnancy
    Quintino, M. P.
    Simoes, R. S.
    Oliveira, F. H. M.
    Oliveira-Filho, R. M.
    Simoes, M. J.
    Nakamura, M. U.
    Kulay, L., Jr.
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2007, 34 (04): : 232 - 235
  • [29] Risk of metabolic abnormalities in HIV-infected patients starting lopinavir-ritonavir containing antiretroviral therapy: a prospective cohort study
    Martinez, E
    Domingo, P
    Galindo, MJ
    Milinkovic, A
    Arroyo, JA
    Baldovi, F
    de Lazzari, E
    Gatell, JM
    ANTIVIRAL THERAPY, 2003, 8 (04) : L80 - L81
  • [30] Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children
    Galán, I
    Jiménez, JL
    Gonz lez-Rivera, M
    De José, MI
    Navarro, ML
    Ramos, JT
    Mellado, MJ
    Gurbindo, MD
    Bellón, JM
    Resino, S
    Cabrero, E
    Muñoz-Fern ndez, MA
    AIDS, 2004, 18 (02) : 247 - 255